Boston Scientific Corp (BSX)vsLENSAR Inc (LNSR)
BSX
Boston Scientific Corp
$48.55
-0.34%
HEALTHCARE · Cap: $70.87B
LNSR
LENSAR Inc
$5.74
0.00%
HEALTHCARE · Cap: $67.78M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 35624% more annual revenue ($20.61B vs $57.70M). LNSR leads profitability with a 50.9% profit margin vs 17.3%. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
LNSR
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.4%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Margin of Safety
-85.1%
Fair Value
$6.71
Current Price
$5.74
$0.97 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Every $100 of equity generates 36 in profit
Keeps 51 of every $100 in revenue as profit
Strong operational efficiency at 49.2%
Conservative balance sheet, low leverage
Areas to Watch
No major concerns identified
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Revenue declined 5.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : LNSR
The strongest argument for LNSR centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 50.9% and operating margin at 49.2%.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : LNSR
The primary concerns for LNSR are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
BSX profiles as a mature stock while LNSR is a declining play — different risk/reward profiles.
LNSR carries more volatility with a beta of 0.87 — expect wider price swings.
BSX is growing revenue faster at 11.6% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 53/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
LENSAR Inc
HEALTHCARE · MEDICAL DEVICES · USA
LENSAR, Inc., a commercial stage medical device company, is focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company is headquartered in Orlando, Florida.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?